ZLD2218
Product Specifications
UNSPSC Description
Considerable studies confirmed that BRD4 inhibition ameliorated kidney injury and fibrosis ,and ZLD2218 exhibited the most potent inhibitory activity against BRD4, with the IC50 value of 107 nM
Target Antigen
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/zld2218.html
Solubility
10 mM in DMSO
Smiles
O=C1C2=C(C(C3=CC4=C(C=CN4CC5=NC=CC=C5)C=C3)=CN1C)C=CN2
Molecular Weight
354.40
References & Citations
[1]Tao S,et al. Discovery of indol-6-yl-pyrrolo[2,3-c]pyridin-7-one derivatives as bromodomain-containing protein 4 (BRD4) inhibitors for the treatment of kidney fibrosis. Eur J Med Chem. 2022 Mar 5;231:114153.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-144236/ZLD2218-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-144236/
Clinical Information
No Development Reported
CAS Number
2713974-32-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items